Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells.
3D cancer cultures
Patient derived 3D cultures
Renal cancer
Renal cancer mutations
Tumouroids
Journal
Journal of cell communication and signaling
ISSN: 1873-9601
Titre abrégé: J Cell Commun Signal
Pays: Netherlands
ID NLM: 101308338
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
17
12
2021
accepted:
04
01
2022
pubmed:
2
2
2022
medline:
2
2
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Recent advancements in 3D in vitro culture have allowed for the development of cancer tissue models which accurately recapitulate the tumour microenvironment. Consequently, there has been increased innovation in therapeutic drug screening. While organoid cultures show great potential, they are limited by the time scale of their growth in vitro and the dependence upon commercial matrices, such as Matrigel, which do not allow for manipulations of their composition or mechanical properties. Here, we show a straightforward approach for the isolation and culture of primary human renal carcinoma cells and matched non-affected kidney. This approach does not require any specific selection for cancer cells, and allows for their direct culture in amenable 3D collagen-based matrices, with the preservation of cancer cells as confirmed by NGS sequencing. This method allows for culture of patient-derived cancer cells in 3D microenvironment, which can be used for downstream experimentation such as investigation of cell-matrix interaction or drug screening.
Identifiants
pubmed: 35102500
doi: 10.1007/s12079-022-00666-2
pii: 10.1007/s12079-022-00666-2
pmc: PMC9733748
doi:
Types de publication
Journal Article
Langues
eng
Pagination
637-648Subventions
Organisme : Invention for Innovation Programme
ID : II-LA-0813-20002
Informations de copyright
© 2022. Crown.
Références
PLoS One. 2011 May 04;6(5):e19337
pubmed: 21573239
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Pathobiology. 2016;83(6):277-86
pubmed: 27225469
Cell Tissue Res. 1991 Jun;264(3):563-76
pubmed: 1868523
Investig Clin Urol. 2020 Mar;61(2):216-223
pubmed: 32158973
J Natl Cancer Inst. 1979 Oct;63(4):893-902
pubmed: 480384
BMC Cancer. 2011 Jun 13;11:244
pubmed: 21668985
Sci Rep. 2016 Apr 28;6:25220
pubmed: 27121191
Cell Rep. 2017 Dec 12;21(11):3298-3309
pubmed: 29241554
Cell. 2014 Sep 25;159(1):163-175
pubmed: 25201529
Acta Biomater. 2013 Aug;9(8):7917-26
pubmed: 23624217
Cell Stem Cell. 2016 Jun 2;18(6):827-838
pubmed: 27212702
Med Mol Morphol. 2014 Jun;47(2):68-75
pubmed: 23529139
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Physiol Rep. 2017 Jun;5(11):
pubmed: 28596300
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Oncotarget. 2016 Jun 21;7(25):38467-86
pubmed: 27509260
Cancer Res. 1990 Sep 1;50(17):5531-6
pubmed: 2386958
Clin Cancer Res. 2007 Jan 1;13(1):161-9
pubmed: 17200351
Nat Commun. 2020 Mar 11;11(1):1310
pubmed: 32161258
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Cell Death Dis. 2019 Feb 27;10(3):201
pubmed: 30814510
J Tissue Eng. 2014 Jul 17;5:2041731414544183
pubmed: 25383169
Cancer. 2009 May 15;115(10 Suppl):2282-9
pubmed: 19402071
Biomed Res Int. 2014;2014:739494
pubmed: 25126575
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Sci Rep. 2017 Mar 09;7:44045
pubmed: 28276469
Clin Imaging. 2011 Jul-Aug;35(4):284-7
pubmed: 21724121
Int J Cancer. 1992 Apr 22;51(1):99-107
pubmed: 1563848
Radiol Bras. 2015 May-Jun;48(3):166-74
pubmed: 26185343
J Biomol Screen. 2016 Oct;21(9):931-41
pubmed: 27233291